Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist

Full text
Author(s):
Show less -
Vaz, Camila de Oliveira [1] ; Mazetto Fonseca, Bruna de Moraes [2] ; Nascimento Silva Vasconcelos, Pedro Eduardo [1] ; Bastos, Larissa Brito [3] ; Cursino, Maria Aparecida [4] ; Franca Quintanilha, Julia Coelho [4] ; Tripiquia Vechiatto Mesquita, Gabriela Lisiane [4] ; Rosa dos Santos, Ana Paula [4] ; Jacintho, Bruna Cardoso [5] ; Oliveira, Jose Diogo [5] ; Annichino-Bizzachi, Joyce [6, 5] ; Orsi, Fernanda Andrade [6, 7]
Total Authors: 12
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Pharmacol, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Campinas, SP - Brazil
[3] Univ Estadual Campinas, Sch Pharmaceut Sci, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Sch Med Sci, Dept Med Sci, Campinas, SP - Brazil
[5] Univ Estadual Campinas, Sch Med Sci, Dept Clin Med, Campinas, SP - Brazil
[6] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP - Brazil
[7] Univ Estadual Campinas, Sch Med Sci, Dept Clin Pathol, Campinas R Tessalia Vieira de Camargo 126, Campinas, SP - Brazil
Total Affiliations: 7
Document type: Journal article
Source: Lupus; v. 30, n. 5, p. 707-714, APR 2021.
Web of Science Citations: 0
Abstract

Purpose Primary antiphospholipid syndrome (PAPS) is a chronic autoimmune disorder clinically characterized by thromboembolic events or obstetric complications. Prolonged anticoagulation therapy with vitamin K antagonists (VKA) is the treatment of choice for PAPS patients with thrombosis. However, the efficacy of VKA therapy depends on laboratory monitoring, dose adjustment, adequate lifestyle and adherence to treatment. Difficulties with VKA therapy can affect patients' self-perceived health related quality of life (HRQOL). This study aims to evaluate PAPS patients' HRQOL, therapy adherence and knowledge of treatment. Methods A general Medical Outcome Study Short Form-36 (SF-36) and the Duke Anticoagulation Satisfaction Scale (DASS) were used to access APS-patients self-perceived HRQOL. Treatment adherence was measured by the Treatment Measure Adhesion (TMA) - oral anticoagulant version instrument, and knowledge of VKA treatment was measured using the MedTake test. Results 66 PAPS patients using VKA were assessed. 63% of them were female; the mean age was 41.9 years old, approximately 60% had unprovoked venous thrombosis and one third of the patients had recurrent thrombotic events. The most impacted domain of DASS was ``psychological impacts{''} and the factors associated to anticoagulation related poor HRQOL were: female sex, presence of arterial thrombosis and INR lability. Using the SF-36 instrument, PAPS-patients self-perceived HRQOL was poorer than that of the general Brazilian population and was associated with female sex and presence of cardiovascular risk factors. Conclusion Despite the high adherence to treatment and knowledge of VKA therapy, self-perceived HRQOL is poor in patients with PAPS and is mainly affected by VKA therapy. Searching for better treatment options is warranted. (AU)

FAPESP's process: 16/14172-6 - Investigation of the pathophysiological aspects and novel therapeutic approaches for thromboembolic disorders
Grantee:Joyce Maria Annichino-Bizzacchi
Support Opportunities: Research Projects - Thematic Grants